{"id":173708,"date":"2021-06-10T16:56:37","date_gmt":"2021-06-10T20:56:37","guid":{"rendered":"https:\/\/z3news.com\/w\/?p=173708"},"modified":"2021-09-12T19:25:13","modified_gmt":"2021-09-12T23:25:13","slug":"spike-protein-variants-in-coronavirus-vaccines-are-the-root-cause-of-blood-clots-new-study-finds","status":"publish","type":"post","link":"https:\/\/z3news.com\/w\/spike-protein-variants-in-coronavirus-vaccines-are-the-root-cause-of-blood-clots-new-study-finds\/","title":{"rendered":"Spike protein variants in coronavirus vaccines are the root cause of blood clots, new study finds"},"content":{"rendered":"

(Natural News<\/a>) German researchers claim to have solved the mystery behind the blood clots<\/a> caused by the\u00a0AstraZeneca and Johnson & Johnson coronavirus vaccines.<\/p>\n

In a preprint article posted May 26 on\u00a0Research Square<\/em>, the team reported that the problem lies with the adenovirus vectors used by the two vaccines to deliver genetic instructions inside cells. The researchers said that due to the mechanisms involved in this type of technology, mutant versions of the spike protein are generated in the nucleus and are then secreted outside of cells. They believe that it is these mutant proteins that trigger the blood clots in healthy people who received the\u00a0AstraZeneca or J&J vaccines.<\/p>\n

Adenovirus-based vaccines and their adverse effects<\/p>\n

The formation of blood clots in the brain\u2019s venous sinuses \u2014 also known as\u00a0cerebral venous sinus thrombosis (CVST) \u2014 was first associated with the AstraZeneca vaccine. In Europe, around 150 cases of this thromboembolic event were reported after different countries successfully administered about\u00a017 million doses of the said vaccine.<\/p>\n

Under normal circumstances, CVST is\u00a0considered a rare form of stroke<\/a>, affecting only five people in one million\u00a0each year. Studies\u00a0show that since the middle of the 20th century, the mortality rate of CVST has gone down from 50 percent to a mere 8.3 percent<\/a> due to advances in modern medicine. But since mass vaccinations have begun, CVST has caused the death of one-third of all affected vaccinated individuals in Germany alone.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

(Natural News)
\n German researchers claim to have solved the mystery behind the blood clots caused by the\u00a0AstraZeneca and Johnson & Johnson coronavirus vaccines.
\nIn a preprint article posted May 26 on\u00a0Research Square, the team reported that the problem lies with the adenovirus vectors used by the two vaccines to deliver genetic instructions inside cells. The researchers said that due to the mechanisms involved in this type of technology, mutant versions of the spike protein are generated in the nucleus and are then secreted outside of cells. They believe that it is these mutant proteins that trigger the blood clots in healthy people who received the\u00a0AstraZeneca or J&J vaccines.
\nAdenovirus-based vaccines and their adverse effects
\nThe formation of blood clots in the brain\u2019s venous sinuses \u2014 also known as\u00a0cerebral venous sinus thrombosis (CVST) \u2014 was first associated with the AstraZeneca vaccine. In Europe, around 150 cases of this thromboembolic event were reported after different countries successfully administered about\u00a017 million doses of the said vaccine.
\nUnder normal circumstances, CVST is\u00a0considered a rare form of stroke, affecting only five people in one million\u00a0each year. Studies\u00a0show that since the middle of the 20th century, the mortality rate of CVST has gone down from 50 percent to a mere 8.3 percent due to advances in modern medicine. But since mass vaccinations have begun, CVST has caused the death of one-third of all affected vaccinated individuals in Germany alone.
\nDue to the alarming rise in the incidence of CVST, many European countries abruptly halted the administration of AstraZeneca\u2019s vaccine back in March. Meanwhile, in the U.S., reports of a similar adverse effect emerged following the J&J vaccine rollout. A total of six cases of CVST\u00a0were confirmed by the Centers for Disease Control and Prevention and the Food and Drug Administration on April 13, which led to a pause on the use of the J&J vaccine 10 days later. (Related:\u00a0Denmark PERMANENTLY BANS Johnson & Johnson coronavirus vaccine over blood clot deaths.)
\nAccording to the German researchers, the AstraZeneca and J&J vaccines share striking similarities. Both cause CVST and some cases of splanchnic vein thrombosis (SVT) \u2014 a type of blood clot that involves one or more abdominal veins \u2014 and both affect mostly young women: between 20 to 60 years for the AstraZeneca vaccine and between 18 to 48 for the J&J vaccine. But most importantly, both vaccines were developed using adenovirus vector technology.
\nAdenovirus vector technology makes use of a virus that has been stripped of the genes it needs to replicate in order to deliver a harmless piece of another viral pathogen \u2014 in this case, the Wuhan coronavirus (COVID-19) \u2014 inside cells. The goal of this technology is to induce cells to reproduce the viral protein and trigger the immune system to produce antibodies specific to it. The benefit of doing this is\u00a0that the body will then be prepared to mount a robust response\u00a0to the COVID-19 virus once a real infection occurs.
\nThe adenovirus vectors used in both the\u00a0AstraZeneca and J&J vaccines were engineered to deliver genetic instructions on how to produce the spike protein. This protein is found on the surface of the COVID-19 virus and is recognized by\u00a0ACE2 receptors, which are naturally present on the surfaces of\u00a0different types of\u00a0human cells. The COVID-19 virus is able to infect healthy cells via this protein-receptor interaction.
\nHow\u00a0AstraZeneca, J&J\u00a0vaccines trigger blood clots
\nIn their report, the German researchers pinpointed the delivery mechanism of adenovirus vectors as the primary source of error that leads to blood clotting events. According to studies on the COVID-19 virus, replication of the virus\u2019s genes always happens in the cytosol \u2014 the fluid inside cells \u2014 of infected cells. However, adenovirus vectors transport viral genes inside the nuclei of cells, where these genetic sequences are spliced, or cut, by enzymes,\u00a0resulting in mutant forms of the spike protein. These shorter variants are unable to bind to the cell membrane, so instead of being displayed on the surfaces of cells, they are secreted outside, where they trigger a strong inflammatory response on endothelial cells.
\nThe researchers\u00a0also noted that some of the mutant spike proteins floating in the extracellular space are still capable of binding to ACE2 receptors. Hence, there can be instances when endothelial cells will not only bind spike protein variants, but would also be \u201cdecorated with newly formed antibodies.\u201d This event is sure to trigger severe inflammation, such as by complement-dependent cytotoxicity (CDC). During CDC, red blood cells are recruited by antibody-covered target cells as part of the complement cascade, which eventually leads to cellular disruption or cell lysis. These immune-related responses could be what triggers the thromboembolic events associated with the AstraZeneca and J&J\u00a0vaccines.
\nIn contrast to adenovirus-based vaccines, mRNA-based vaccines like those produced by Pfizer and Moderna rely on lipid nanoparticles to deliver viral genes to muscle cells. These vectors release their cargo into the cytosol as soon as they are taken up by cells. Because of this, translation of the viral mRNA into the spike protein occurs without any modifications to the final product. This, according to the researchers, is why the Pfizer and Moderna vaccines are not associated with CVST.
\nTo circumvent the threat of blood clots\u00a0caused by AstraZeneca and J&J vaccines, the researchers recommend modifying the gene sequence that codes for the spike protein in such a way that it will not be susceptible to splicing. They believe this is the only way the developers can ensure the safety of those who receive either of the two vaccines.
\n\u201cBased on our findings, we strongly suggest that the Spike open reading frames \u2013 wildtype or codon-optimized \u2013 in vector-based vaccines [have] to be re-optimized to avoid unintended splice reactions and to increase the safety of these pharmaceutical products,\u201d the researchers wrote in their report.
\nFor more news on coronavirus vaccines and their adverse effects, visit VaccineInjuryNews.com.
\nSources include:
\nFT.com
\nHopkinsMedicine.org
\nAHAJournals.org
\nFDA.gov 1
\nFDA.gov 2
\nCDC.gov
\nResearchSquare.com<\/p>\n","protected":false},"author":691,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"sfsi_plus_gutenberg_text_before_share":"","sfsi_plus_gutenberg_show_text_before_share":"","sfsi_plus_gutenberg_icon_type":"","sfsi_plus_gutenberg_icon_alignemt":"","sfsi_plus_gutenburg_max_per_row":"","_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":"","_ppma_block_editor_authors":""},"categories":[521],"tags":[],"ppma_author":[948],"class_list":["post-173708","post","type-post","status-publish","format-standard","category-spike-proteins","entry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t